Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONC201 in Recurrent Glioblastoma
NCT02525692Phase 2Terminated
- Sponsor
- Chimerix Inc.
- Start
- Jan 2016
- Primary completion
- Apr 2023
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dordaviprone in glioblastoma (GBM), diffuse midline glioma (DMG), sponsored by Chimerix Inc.. Started Jan 2016; status: terminated.
02
Drugs
dordaviprone
03
Conditions
glioblastoma (GBM)diffuse midline glioma (DMG)
Beyond the preview
Go deeper on NCT02525692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02525692.